Clinical Trials | A Phase III, Randomised, Open-Label, Multicenter Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. The purpose of this study is to determine the effectiveness and tolerability of the investigational study drug Dato-Dxd (datopotamab deruxtecan compared to the standard care of chemotherapy docetaxel. To be eligible for the study, a sample of your lung cancer must be tested to see if the tumor has expression of a protein called TROP2 using a test called TROP2 QCS-NMR. The testing may happen on a previous biopsy or on a new one. In this study, you will be randomly assigned to 1 of 2 treatment arms in this study: Dato-Dxd (the experimental treatment arm) or docetaxel (the standard-of-care treatment arm which is also called the “comparator” treatment arm). This study is open label, meaning both you and your doctor will be aware of the study treatment you are receiving. You have a 50% (1 in 2) chance of being given Dato-Dxd. There is a risk that your NSCLC will not get better, or even get worse during the study if your cancer does not respond to the treatment. It is possible that some patients could have side effects from the study treatments or procedures that we do not know about yet. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. We expect that your taking part in this research will last about 15 months. Additional information found here: [clinical trials link] For questions, contact: [email protected]